Clinical Trial Update: ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 study of ASTX727 is recruiting for recurrent/progressive non-enhancing IDH-mutant gliomas. The trial investigates the oral decitabine/cedazuridine com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Idh-mutant Glioma

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Neurological Cancer | Phase 1 | Status: RECRUITING